AnaptysBio, Inc. (ANAB) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $53.45 (-2.88%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 6, 2026 | John Lee | Truist Financial | $50.00 | -6.5% |
| Mar 5, 2026 | Alex Thompson | Stifel Nicolaus | $85.00 | +59.0% |
| Mar 4, 2026 | Emily Bodnar | H.C. Wainwright | $66.00 | +23.5% |
| Jan 7, 2026 | Michael Yee | UBS | $70.00 | +31.0% |
| Dec 17, 2025 | Etzer Darout | Barclays | $55.00 | +2.9% |
| Nov 10, 2025 | David Nierengarten | Wedbush | $50.00 | -6.5% |
| Nov 10, 2025 | Joon Lee | Truist Financial | $36.00 | -32.7% |
| Oct 15, 2025 | David Nierengarten | Wedbush | $70.00 | +31.0% |
| May 6, 2025 | Yatin Suneja | Guggenheim | $54.00 | +1.0% |
| Feb 4, 2025 | Andy Chen | Wolfe Research | $25.00 | -53.2% |
| Dec 11, 2024 | Emily Bodnar | H.C. Wainwright | $19.00 | -64.5% |
| Nov 6, 2024 | Emily Bodnar | H.C. Wainwright | $52.00 | -2.7% |
| Nov 6, 2024 | David Risinger | Leerink Partners | $45.00 | -15.8% |
| Oct 21, 2024 | Yatin Suneja | Guggenheim | $90.00 | +68.4% |
| Oct 15, 2024 | Yasmeen Rahimi | Piper Sandler | $80.00 | +49.7% |
| Oct 3, 2024 | David Risinger | New Street | $35.00 | -34.5% |
| Aug 15, 2024 | Joon Lee | Truist Financial | $30.00 | -43.9% |
| Apr 16, 2024 | David Risinger | Leerink Partners | $47.00 | -12.1% |
Top Analysts Covering ANAB
ANAB vs Sector & Market
| Metric | ANAB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.07 | 2.25 | 2.42 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +36.5% | +16366.1% | +18.0% |
| P/E Ratio | -138.84 | 3.14 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $23M | $30M | $37M | 4 |
| 2026-12-31 | $29M | $38M | $46M | 4 |
| 2027-03-31 | $15M | $19M | $24M | 4 |
| 2027-06-30 | $17M | $22M | $28M | 3 |
| 2027-09-30 | $39M | $51M | $62M | 3 |
| 2027-12-31 | $54M | $71M | $87M | 3 |
| 2028-12-31 | $277M | $280M | $284M | 7 |
| 2029-12-31 | $130M | $327M | $432M | 3 |
| 2030-12-31 | $186M | $467M | $617M | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.73 | $-0.56 | $-0.39 | 3 |
| 2026-12-31 | $-0.65 | $-0.50 | $-0.35 | 3 |
| 2027-03-31 | $-0.83 | $-0.64 | $-0.44 | 3 |
| 2027-06-30 | $-0.77 | $-0.59 | $-0.41 | 2 |
| 2027-09-30 | $-0.21 | $-0.16 | $-0.11 | 2 |
| 2027-12-31 | $0.20 | $0.29 | $0.38 | 2 |
| 2028-12-31 | $-1.83 | $-0.34 | $1.28 | 7 |
| 2029-12-31 | $-0.31 | $-0.22 | $-0.05 | 2 |
| 2030-12-31 | $0.44 | $2.04 | $2.89 | 5 |
Frequently Asked Questions
What is the analyst consensus for ANAB?
The consensus among 14 analysts covering AnaptysBio, Inc. (ANAB) is Buy with an average price target of $73.67.
What is the highest price target for ANAB?
The highest price target for ANAB is $90.00, set by Yatin Suneja at Guggenheim on 2024-10-21.
What is the lowest price target for ANAB?
The lowest price target for ANAB is $19.00, set by Emily Bodnar at H.C. Wainwright on 2024-12-11.
How many analysts cover ANAB?
14 analysts have issued ratings for AnaptysBio, Inc. in the past 12 months.
Is ANAB a buy or sell right now?
Based on 14 analyst ratings, ANAB has a consensus rating of Buy (2.07/5) with a +36.5% upside to the consensus target of $73.67.
What are the earnings estimates for ANAB?
Analysts estimate ANAB will report EPS of $-0.56 for the period ending 2026-09-30, with revenue estimated at $30M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.